Scotiabank Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a research report released on Thursday,Benzinga reports. The firm currently has a sector perform rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft cut their price objective […]
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a research report released on Thursday,Benzinga reports. The firm currently has a sector perform rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft cut their price objective […]
